CureVac (NASDAQ:CVAC) Stock Price Up 3.6% – Time to Buy?

Shares of CureVac (NASDAQ:CVAC) shot up 3.6% during mid-day trading on Friday . The company traded as high as $3.19 and last traded at $3.16. 170,744 shares changed hands during trading, a decline of 79% from the average session volume of 811,117 shares. The stock had previously closed at $3.05.

Wall Street Analyst Weigh In

Separately, JMP Securities restated a “market outperform” rating and issued a $16.00 price objective on shares of CureVac in a report on Monday, September 16th.

CureVac Trading Up 3.9 %

The firm has a fifty day moving average of $2.86 and a 200-day moving average of $3.12. The company has a debt-to-equity ratio of 0.05, a quick ratio of 6.19 and a current ratio of 6.20. The stock has a market capitalization of $709.70 million, a price-to-earnings ratio of 5.76, a P/E/G ratio of 0.24 and a beta of 2.59.

Hedge Funds Weigh In On CureVac

Several hedge funds and other institutional investors have recently bought and sold shares of CVAC. Barclays PLC purchased a new stake in shares of CureVac during the third quarter valued at approximately $67,000. Public Employees Retirement System of Ohio acquired a new stake in CureVac during the 3rd quarter valued at $91,000. Jane Street Group LLC increased its stake in CureVac by 239.0% during the 3rd quarter. Jane Street Group LLC now owns 79,247 shares of the company’s stock worth $235,000 after buying an additional 55,867 shares during the period. Integrated Wealth Concepts LLC acquired a new position in CureVac in the 3rd quarter worth $35,000. Finally, China Universal Asset Management Co. Ltd. lifted its holdings in CureVac by 63.7% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 43,143 shares of the company’s stock worth $127,000 after buying an additional 16,792 shares in the last quarter. 17.26% of the stock is owned by institutional investors and hedge funds.

CureVac Company Profile

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.